Valosin containing protein associated fronto-temporal lobar degeneration: Clinical presentation, pathologic features and pathogenesis

Current Alzheimer Research

Volumn 8, Issue 3, 2011, Pages 252-260

  Weihl, C C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FTD; IBMPFD; Neurodegeneration; TDP 43; Ubiquitin; VCP

Indexed keywords

ATAXIN 3; CREATINE KINASE; HISTONE DEACETYLASE 6; MUTANT PROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN P62; TAR DNA BINDING PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; VALOSIN CONTAINING PROTEIN;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BIOGENESIS; BRAIN CORTEX ATROPHY; CELL DEGENERATION; CELL DIVISION; CELL FUSION; CELL MATURATION; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CELL ORGANELLE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; CYTOPLASM; CYTOSOL; ENZYME INHIBITION; FAMILY HISTORY; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; INCLUSION BODY MYOPATHY; LYSOSOME; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SKELETAL MUSCLE; TDP 43 PROTEINOPATHY;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL CYCLE PROTEINS; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; MYOSITIS, INCLUSION BODY;

EID: 79956257399     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511795563773     Document Type: Article

References (63)

1. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease ofbone and frontotemporal dementia is caused by mutant valosincontainingprotein. Nat Genet 36(4): 377-381 (2004).
2. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy,Paget disease of bone, and frontotemporal dementia. AlzheimerDis Assoc Disord 19 Suppl 1: S44-447 (2005).
3. Guyant-Marechal L, Laquerriere A, Duyckaerts C, Dumanchin C, Bou J, Dugny F, et al. Valosin-containing protein gene mutations:clinical and neuropathologic features. Neurology 67(4): 644-645.(2006).
4. Haubenberger D, Bittner RE, Rauch-Shorny S, Zimprich F, Mannhalter C, Wagner L, et al. Inclusion body myopathy and Paget diseaseis linked to a novel mutation in the VCP gene. Neurology 65(8): 1304-1305 (2005).
5. Hubbers CU, Clemen CS, Kesper K, Boddrich A, Hofmann A, Kamarainen O, et al. Pathological consequences of VCP mutationson human striated muscle. Brain Sep 19 (2006).
6. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M,Boycott K, et al. Clinical studies in familial VCP myopathy associatedwith Paget disease of bone and frontotemporal dementia. Am JMed Genet A 146A(6): 745-757 (2008).
7. van der Zee J, Pirici D, Van Langenhove T, Engelborghs S, Vandenberghe R, Hoffmann M, et al. Clinical heterogeneity in 3 unrelatedfamilies linked to VCP p.Arg159His. Neurology 73(8): 626-632 (2009).
8. Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, et al. Clinical delineation and localization to chromosome9p13.3-p12 of a unique dominant disorder in four families:hereditary inclusion body myopathy, Paget disease of bone, andfrontotemporal dementia. Mol Genet Metab 74(4): 458-475 (2001).
9. Stojkovic T, Hammoudael H, Richard P, Lopez de Munain A, Ruiz-Martinez J, Gonzalez PC, et al. Clinical outcome in 19 Frenchand Spanish patients with valosin-containing protein myopathy associatedwith Paget's disease of bone and frontotemporal dementia.Neuromus Disord 19(5):316-323 (2009).
10. Krause S, Gohringer T, Walter MC, Schoser BG, Reilich P, Linn J, et al. Brain imaging and neuropsychology in late-onset dementiadue to a novel mutation (R93C) of valosin-containing protein. ClinNeuropathol 26(5): 232-420 (2007).
11. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing proteindisease: inclusion body myopathy with Paget's disease of the boneand fronto-temporal dementia. Neuromuscul Disord 19(5): 308-315. (2009).
12. Kumar KR, Needham M, Mina K, Davis M, Brewer J, Staples C, et al. Two Australian families with inclusion-body myopathy, Paget'sdisease of bone and frontotemporal dementia: Novel clinical andgenetic findings. Neuromus Disord.
13. Schroder R, Watts GD, Mehta SG, Evert BO, Broich P, Fliessbach K, et al. Mutant valosin-containing protein causes a novel type offrontotemporal dementia. Ann Neurol 57(3): 457-461 (2005).
14. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, et al. Novel ubiquitin neuropathology in frontotemporaldementia with valosin-containing protein gene mutations. JNeuropathol Exp Neurol 65(6): 571-81 (2006).
15. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degenerationwith ubiquitin inclusions. Am J Pathol 171(1): 227-240(2007).
16. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporaldementia with VCP gene mutations. J Neuropathol Exp Neuro l66(2): 152-157 (2007).
17. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobardegeneration and amyotrophic lateral sclerosis. Science 314(5796):130-133 (2006).
18. Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, et al. Valosin-containing protein (VCP) is required forautophagy and is disrupted in VCP disease. J Cell Biol 187(6): 875-888 (2009).
19. Hubbers CU, Clemen CS, Kesper K, Boddrich A, Hofmann A, Kamarainen O, et al. Pathological consequences of VCP mutationson human striated muscle. Brain 130(Pt 2): 381-393 (2007).
20. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al.TDP-43 accumulation in inclusion body myopathy muscle suggestsa common pathogenic mechanism with frontotemporal dementia. JNeurol Neurosurg Psychiatry 79(10): 1186-1189 (2008).
21. Watts GD, Thomasova D, Ramdeen SK, Fulchiero EC, Mehta SG,Drachman DA, et al. Novel VCP mutations in inclusion body myopathyassociated with Paget disease of bone and frontotemporaldementia. Clin Genet 72(5): 420-426 (2007).
22. Greenberg SA, Watts GD, Kimonis VE, Amato AA, Pinkus JL.Nuclear localization of valosin-containing protein in normal muscleand muscle affected by inclusion-body myositis. Muscle Nerve(2007).
23. Halawani D, Latterich M. p97: The cell's molecular purgatory? MolCell 22(6): 713-717 (2006).
24. Dreveny I, Pye VE, Beuron F, Briggs LC, Isaacson RL, Matthews SJ, et al. p97 and close encounters of every kind: a brief review. Biochem Soc Trans 32(Pt 5): 715-20 (2004).
25. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitinchain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 3(8): 740-4 (2001).
26. Wojcik C, Rowicka M, Kudlicki A, Nowis D, McConnell E, Kujawa M, et al. Valosin-containing protein (p97) Is a regulator of ERstress and of the degradation of N-End rule and ubiquitin-fusiondegradation pathway substrates in mammalian cells. Mol Biol Cell (2006).
27. Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmicreticulum-associated protein degradation. Mol Cell Biol 22(2): 626-634 (2002).
28. Dalal S, Rosser MF, Cyr DM, Hanson PI. Distinct roles for theAAA ATPases NSF and p97 in the secretory pathway. Mol BiolCell 15(2): 637-648 (2004).
29. Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement ofvalosin-containing protein, an ATPase Co-purified with Ikappa-Balpha and 26 S proteasome, in ubiquitin-proteasome-mediateddegradation of IkappaBalpha. J Biol Chem 273 (6): 3562-3573(1998).
30. Alexandru G, Graumann J, Smith GT, Kolawa NJ, Fang R, Deshaies RJ. UBXD7 binds multiple ubiquitin ligases and implicatesp97 in HIF1alpha turnover. Cell 134(5): 804-16 (2008).
31. Ramadan K, Bruderer R, Spiga FM, Popp O, Baur T, Gotta M, etal. Cdc48/p97 promotes reformation of the nucleus by extractingthe kinase Aurora B from chromatin. Nature 450 (7173): 1258-1262(2007).
32. Janiesch PC, Kim J, Mouysset J, Barikbin R, Lochmuller H, Cassata G, et al. The ubiquitin-selective chaperone CDC-48/p97 linksmyosin assembly to human myopathy. Nat Cell Bio 9 (4): 379-390(2007).
33. Kobayashi T, Tanaka K, Inoue K, Kakizuka A. Functional ATPaseactivity of p97/valosin-containing protein (VCP) is required for thequality control of endoplasmic reticulum in neuronally differentiatedmammalian PC12 cells. J Biol Chem 277 (49): 47358-47365(2002).
34. Mizuno Y, Hori S, Kakizuka A, Okamoto K. Vacuole-creatingprotein in neurodegenerative diseases in humans. Neurosci Lett 343(2): 77-80 (2003).
35. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular responseto misfolded proteins. J Cell Biol 143(7): 1883-98 (1998).
36. Ju JS, Miller SE, Hanson PI, Weihl CC. Impaired protein aggregatehandling and clearance underlie the pathogenesis of p97/VCPassociateddisease. J Biol Chem 283(44): 30289-99 (2008).
37. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essentiallink between autophagy and the UPS. Nature 447(7146):859-63 (2007).
38. Halawani D, LeBlanc AC, Rouiller I, Michnick SW, Servant MJ, Latterich M. Hereditary inclusion body myopathy-linked p97/VCPmutations in the NH2 domain and the D1 ring modulate p97/VCPATPase activity and D2 ring conformation. Mol Cell Biol 29(16):4484-94 (2009).
39. Weihl CC, Dalal S, Pestronk A, Hanson PI. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum Mol Genet 15 (2): 189-199(2006).
40. Manno A, Noguchi M, Fukushi J, Motohashi Y, Kakizuka A., Enhanced A. TPase activities as a primary defect of mutant valosincontainingproteins that cause inclusion body myopathy associatedwith Paget disease of bone and frontotemporal dementia. GenesCells 15(8): 911-922.
41. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expressionof inclusion body myopathy associated mutant p97/VCPcauses weakness and ubiquitinated protein inclusions in mice. HumMol Genet 16(8): 919-928 (2007).
42. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenicmice expressing mutant forms VCP/p97 recapitulate the full spectrumof IBMPFD including degeneration in muscle, brain andbone. Hum Mol Genet Feb 19.
43. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, et al. Parkinsonismand impaired axonal transport in a mouse model of frontotemporaldementia. Proc Natl Acad Sci USA 105 (41): 15997-16002 (2008).
44. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al.Loss of autophagy in the central nervous system causes neurodegenerationin mice. Nature 441(7095): 880-884 (2006).
45. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neuralcells causes neurodegenerative disease in mice. Nature 441(7095):885-889 (2006).
46. Tresse E, Salomons FA, Vesa J, Bott LC, Kimonis V, Yao TP, etal. VCP/p97 is essential for maturation of ubiquitin-containingautophagosomes and this function is impaired by mutations thatcause IBMPFD. Autophagy 6(2): 1-11 (2010).
47. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubulesare required for autophagic degradation of aggregated huntingtin. J Biol Chem 280(48): 40282-40292 (2005).
48. Fu L, Sztul E. ER-associated complexes (ERACs) containing aggregatedcystic fibrosis transmembrane conductance regulator(CFTR) are degraded by autophagy. Eur J Cell Biol 88 (4): 215-226(2009).
49. Wojcik C, Yano M, DeMartino GN. RNA interference of valosincontainingprotein (VCP/p97) reveals multiple cellular roles linkedto ubiquitin/proteasome-dependent proteolysis. J Cell Sci 117(Pt2): 281-92 (2004).
50. Kobayashi T, Manno A, Kakizuka A. Involvement of valosincontainingprotein (VCP)/p97 in the formation and clearance of abnormalprotein aggregates. Genes Cells 12(7): 889-901 (2007).
51. Malicdan MC, Noguchi S, Nonaka I, Saftig P, Nishino I. Lysosomalmyopathies: an excessive build-up in autophagosomes is toomuch to handle. Neuromusc Disord 18(7): 521-529 (2008).
52. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutationof the gene encoding sequestosome 1 (SQSTM1/p62) in Paget diseaseof bone. Am J Hum Genet 70(6): 1582-1588 (2002).
53. Lee JA, Beigneux A, Ahmad ST, Young SG, Gao FB. ESCRT-IIIdysfunction causes autophagosome accumulation andneurodegeneration. Curr Biol 17(18): 1561-1567 (2007).
54. Filimonenko M, Stuffers S, Raiborg C, Yamamoto A, Malerod L, Fisher EM, et al. Functional multivesicular bodies are required forautophagic clearance of protein aggregates associated with neurodegenerativedisease. J Cell Biol 2007 Nov 5;179(3):485-500.
55. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL,Hummerich H, et al. Mutations in the endosomal ESCRTIIIcomplexsubunit CHMP2B in frontotemporal dementia. Nat GenetAug; 37(8): 806-8 (2005).
56. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, et al.HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J Jan 14.
57. Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUSabout TDP-43. Cell Mar 20; 136(6): 1001-4 (2009).
58. Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R,Baralle FE. Depletion of TDP-43 affects Drosophila motoneuronsterminal synapsis and locomotive behavior. FEBS Lett 583(10):1586-92 (2009).
59. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S.Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhancedby a mutation associated with familial amyotrophic lateralsclerosis. J Neurosci 30(2): 639-649.
60. Gitcho MA, Strider J, Carter D, Taylor-Reinwald L, Forman MS, Goate AM, et al. VCP mutations causing frontotemporal lobar degenerationdisrupt localization of TDP-43 and induce cell death. JBiol Chem 284(18): 12384-12398 (2009).
61. Urushitani M, Sato T, Bamba H, Hisa Y, Tooyama I. Synergisticeffect between proteasome and autophagosome in the clearance ofpolyubiquitinated TDP-43. J Neurosci Res 88(4): 784-797.
62. Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, et al. TDP-43 mediates degeneration in a novel Drosophilamodel of disease caused by mutations in VCP/p97. J Neurosci 30(22): 7729-39.
63. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutationsas a cause of familial ALS. Neuron 68(5): 857-64.